485 related articles for article (PubMed ID: 26088100)
1. Functions of Shp2 in cancer.
Zhang J; Zhang F; Niu R
J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
[TBL] [Abstract][Full Text] [Related]
2. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
4. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
5. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
[TBL] [Abstract][Full Text] [Related]
7. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
[TBL] [Abstract][Full Text] [Related]
8. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
9. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
11. Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
[TBL] [Abstract][Full Text] [Related]
12. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
[TBL] [Abstract][Full Text] [Related]
13. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
16. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine phosphatase Shp2 in development and cancer.
Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
[TBL] [Abstract][Full Text] [Related]
18. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
Wu J; Zhang H; Zhao G; Wang R
Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
[TBL] [Abstract][Full Text] [Related]
19. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
20. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]